



An efficient potassium cyanide-promoted synthesis of 2-arylbenzoxazoles from [4.3.0]boron heterobicycles

Heraclio López-Ruiz^{a,*}, Horacio Briseño-Ortega^a, Susana Rojas-Lima^a, Rosa Santillán^b, Norberto Farfán^c

^a Centro de Investigaciones Químicas, Universidad Autónoma del Estado de Hidalgo, Carretera Pachuca-Tulancingo Km 4.5, Ciudad Universitaria, 42184 Mineral de la Reforma, Mexico

^b Departamento de Química, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional Apto. Postal 14-740, 07000 México D.F., Mexico

^c Departamento de Química Orgánica, Facultad de Química, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, 04510, México D.F., Mexico

ARTICLE INFO

Article history:

Received 1 September 2009

Revised 5 March 2010

Accepted 8 March 2010

Available online 15 March 2010

Keywords:

Schiff bases

Boronates

Potassium cyanide

2-Arylbenzoxazoles

NMR

ABSTRACT

The 2-arylbenzoxazoles **3a–f** were produced in moderate to excellent yields merely by stirring a potassium cyanide (3 equiv)-containing methanol solution of the borobicyclic compounds **1a–f** at room temperature. These compounds were fully characterized spectroscopically [IR, ¹H, and ¹³C NMR and X-ray analysis (**3a**)] and by elemental analysis.

Crown Copyright © 2010 Published by Elsevier Ltd. All rights reserved.

There has been a recent surge in the development of new benzoxazole syntheses because of their occurrence in a number of natural products¹, and their potential use as cytotoxic agents², cathepsin S inhibitors³, HIV reverse transcriptase inhibitors⁴, estrogen receptor agonists⁵, selective peroxisome proliferator-activated receptor antagonists⁶, anticancer agents⁷, and orexin-1 receptor antagonists.⁸ They have also found application as herbicides and as fluorescent-whitening agent dyes.⁹ The methods which have been used to provide access to benzoxazoles include (a) conventional thermal- or microwave-accelerated condensation of 2-aminophenols with carboxylic acid derivatives under strongly acidic conditions,¹⁰ (b) metal-catalyzed cyclization of 2-halo *N*-acylanilines,¹¹ and (c) oxidative cyclization of the Schiff bases derived from 2-aminophenols and aldehydes using oxidants such as 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ),¹² PhI(OAc)₂,¹³ NiO₂,¹⁴ Ba(MnO₄)₂,¹⁵ pyridinium chlorochromate (PCC),¹⁶ Mn(OAc)₃,¹⁷ PbO₂,¹⁸ Pb(OAc)₄,¹⁹ ThClO₄,²⁰ and Pd(OAc)₂.²¹ (Fig. 1). In addition, oxidative cyclization conditions considerably milder than those referred above have been described for the generation of benzoxazoles from the Schiff bases derived from 2-aminophenols.²² Herein, we describe an exceptionally mild method of generating benzoxazoles from the boron-containing heterocyclic systems **1a–f**.

In continuation of our recent studies involving the boron complexes derived from Schiff bases,^{23,24} we reacted a methanolic solution of the very readily available^{23–26} boron-containing heterocyclic compound **1a** (see Scheme 1 for synthesis) with excess potassium cyanide at room temperature, with the expectation of obtaining the tetracyclic nitrile **2a** (Scheme 1). The only compound isolated, however, from the reaction mixture was the 2-arylbenzoxazole derivative **3a** (61 % yield). The 2-arylbenzoxazoles **3b–f** were similarly obtained from compounds **1b–f** (See Scheme 2). The structures of the benzoxazole derivatives were unequivocally






Figure 1. X-ray structure of **3a**.

* Corresponding author. Tel.: +52 7717172000x2209; fax: +52 7717172000x 6502.


E-mail addresses: heraclio@uaeh.edu.mx, heracliol@yahoo.com.mx (H. López-Ruiz).



Scheme 1.



Scheme 2.

Figure 2. Dimeric structure for **3a** formed by intermolecular hydrogen bonding.

established by the usual spectroscopic means²⁷, as well as by an X-ray crystal structure for compound **3a** (Fig. 2, vide infra).²⁸ Thus, the ¹H NMR spectra of these compounds did not possess signals for H-7 (8.29–8.46, see Scheme 1), but did show a low field absorption at δ 11.2–11.58 typical of an H-bonded hydroxyl group (to the C=N moiety; see also Fig. 2 below). In addition, the IR spectra showed absorption bands at 1631–1627 cm⁻¹ (C=N) and 1591–1557 cm⁻¹ (O=C=N moiety) which are characteristic of the five-membered ring of benzoxazoles. Furthermore, the Raman spectrum of compound **3e** shows bands expected for both the C=N (1630 cm⁻¹) and O=C=N (1551 cm⁻¹) groups.

A crystal suitable for X-ray diffraction was obtained for compound **3a** and the molecular structure is shown in Figure 2.²⁸ The existence of an intramolecular hydrogen bond between the phenolic OH group and benzoxazole N-atom is consistent with the observed N–HO(2) distance (2.66 Å) and the N–H(O2) angle (147.7°). The molecular packing reveals that interaction present at the oxygen (O2) and hydrogen atoms (CH₃) forms a dimeric structure in the solid state (Fig. 2). The H₃C–(O2) intermolecular distance is 3.625 Å and the C(14)–H–(O2) angle is 172.8°, characteristic of a weak intermolecular bond.

In conclusion, an efficient method for the synthesis of 2-arylbenzoxazoles has been developed from the [4.3.0] boron heterobicyclic compounds **1a–f** containing a dative N–B bond. This unprecedented reaction occurs rapidly at room temperature. Compounds **3a–f** were fully characterized by ¹H and ¹³C NMR spectroscopy and by X-ray analysis for **3a**.

Acknowledgments

We are indebted to Dr. Joseph M. Muchowski for friendly, helpful discussions and to CONACyT for financial support (Grant J49336-Q).

References and notes

- (a) Deluca, M. R.; Kervin, S. M. *Tetrahedron Lett.* **1997**, *38*, 199–202; (b) Sato, Y.; Yamada, M.; Yoshida, S.; Soneda, T.; Ishikawa, M.; Nizato, T.; Suzuli, K.; Konno, F. *J. Med. Chem.* **1998**, *41*, 3015–3021; (c) Temiz, O.; Oren, I.; Sener, E.; Yalcin, I.; Ucarturk, N. *Farmaco* **1998**, *53*, 337–341; (d) Wang, C.; Widon, J.; Petronijevic, F.; Burnett, J. C.; Nuss, J. E.; Bavari, S.; Gussio, R.; Wipf, P. *Heterocycles* **2009**, *79*, 487–520.
- (a) Rodriguez, A. D.; Ramirez, C.; Rodriguez, I. I.; Gonzalez, E. *Org. Lett.* **1999**, *1*, 527–530; (b) Davidson, J. P.; Corey, E. J. *J. Am. Chem. Soc.* **2003**, *125*, 13486–13489; (c) Ueki, M.; Ueno, K.; Miyadoh, S.; Abe, K.; Shibata, K.; Taniguchi, M.; Oi, S. *J. Antibiot.* **1993**, *46*, 1089–1094; (d) Sato, S.; Kajira, T.; Noguchi, M.; Takehana, K.; Kobavashi, T.; Tsuji, T. *J. Antibiot.* **2001**, *54*, 102–104; (e) Don, M.-J.; Shen, C.-C.; Lin, Y.-L.; Syu, W., Jr.; Ding, Y.-H.; Sun, C.-M. *J. Nat. Prod.* **2005**, *68*, 1066–1070.

3. Tully, D. C.; Liu, H.; Alper, P. B.; Chatterjee, A. K.; Epple, R.; Roberts, M. J.; Williams, J. A.; Nguyen, K. T.; Woodmansee, D. H.; Tumanut, C.; Li, J.; Spraggon, G.; Chang, J.; Tuntland, T.; Harris, J. L.; Karanewsky, D. S. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1975–1980.
4. Grobler, J. A.; Dornadula, G.; Rice, R. M.; Simcoe, A. L.; Hazuda, D. J.; Miller, M. D. *J. Biol. Chem.* **2007**, *282*, 8005–8010.
5. Leventhal, L.; Brandt, M. R.; Cummons, T. A.; Piesla, M. J.; Rogers, K. E.; Harris, H. A. *Eur. J. Pharmacol.* **2006**, *553*, 146–148.
6. Nishiu, J.; Ito, M.; Ishida, Y.; Kakutani, M.; Shibata, T.; Matsushita, M.; Shindo, M. *Diabetes Obes. Metab.* **2006**, *8*, 508–516.
7. Easmon, J.; Pürstinger, G.; Thies, K.-S.; Heinisch, G.; Hofmann, J. *J. Med. Chem.* **2006**, *49*, 6343–6350.
8. Rasmussen, K.; Hsu, M.-A.; Yang, Y. *Neuropsychopharmacology* **2007**, *32*, 786–792.
9. Leaver, I. H.; Milligam, B. *Dyes Pigm.* **1984**, *5*, 109–144.
10. (a) For a general overview of synthesis methods to benzoxazoles, see: (a) Boyd, G.V. In *Science of Synthesis: Houben–Weyl Methods of Molecular Transformations*; Schumann, E., Ed.; Stuttgart: Thieme, 2002; Vol. 11, pp 481–492; (b) Lin, A.; Yang, L. *Tetrahedron Lett.* **2005**, *46*, 4315–4319; (c) Kawashita, Y.; Nakamichi, N.; Kawabata, H.; Hayashi, M. *Org. Lett.* **2003**, *5*, 3713–3715; (d) Kidwai, M.; Bansal, V.; Saxena, A.; Aery, S.; Mozudar, S. *Tetrahedron Lett.* **2006**, *47*, 8049–8053; (e) Kumar, D.; Rudrawar, S.; Chakaborti, A. K. *Aust. J. Chem.* **2008**, *61*, 881–887; (f) Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W. *J. Med. Chem.* **2008**, *51*, 260–270; (g) Orlando, C. M.; Wirth, J. G.; Heath, D. R. *J. Org. Chem.* **1970**, *9*, 3147–3149.
11. (a) Eviandar, G.; Batey, R. A. *J. Org. Chem.* **2006**, *71*, 1802–1808; (b) Viirre, R. D.; Eviandar, G.; Batey, R. A. *J. Org. Chem.* **2008**, *73*, 3452–3459; (c) Bonnamour, J.; Bolm, C. *Org. Lett.* **2008**, *10*, 2665–2667; (d) Saha, P.; Ramana, T.; Purkait, N.; Ali, M. A.; Paul, R.; Punniyamurthy, T. *J. Org. Chem.* **2009**, *74*, 8719–8725; (e) Kantam, M. L.; Venkanna, G. T.; Kumar, K. B. S.; Balasubrahmanyam, V.; Bhargava, S. *Synlett* **2009**, *11*, 1753–1756.
12. Chang, J.; Zhao, K.; Pan, S. *Tetrahedron Lett.* **2002**, *43*, 951–954.
13. Warma, R. S.; Saini, R. K.; Prakash, O. *Tetrahedron Lett.* **1997**, *38*, 2621–2622.
14. Nakagawa, K.; Onoue, H.; Sugita, J. *Chem. Pharm. Bull.* **1961**, *12*, 1135–1138.
15. Srivastava, R. G.; Venkataramani, R. S. *Synth. Commun.* **1988**, *18*, 1537–1544.
16. Praveen, C.; Kumar, K. H.; Muralidharan, D.; Perumal, P. T. *Tetrahedron* **2008**, *64*, 2369–2374.
17. Varma, R. S.; Kumar, D. *J. Heterocycl. Chem.* **1998**, *35*, 1539–1540.
18. Nakawawa, K.; Onoue, H.; Sugita, J. *Chem. Pharm. Bull.* **1964**, *12*, 1135–1138.
19. Stephens, F. F.; Bower, J. D. *J. Chem. Soc.* **1949**, 2971–2972.
20. Park, K. H.; Jun, K.; Shin, S. R.; Oh, S. W. *Tetrahedron Lett.* **1996**, *37*, 8869–8870.
21. Chen, W.-H.; Pang, Y. *Tetrahedron Lett.* **2009**, *50*, 6680–6683.
22. (a) Shoar, R. H.; Heidary, M.; Farzaneh, M.; Malakouti, R. *Synth. Commun.* **2009**, *39*, 1742–1751; (b) Chen, Y.-X.; Qian, L. F.; Zhang, W.; Han, B. *Angew. Chem., Int. Ed.* **2008**, *47*, 9330–9333; (c) Baltork, I. M.; Moghadam, M.; Tangestaninejad, S.; Mirkhani, V.; Zolfigol, M. A.; Hojati, S. F. *J. Iran. Chem. Soc.* **2008**, *5*, S65–S70; (d) Ponnala, S.; Sahu, D. P. *Synth. Commun.* **2006**, *36*, 2189–2194; (e) Kawashita, Y.; Nakamishi, N.; Kawabata, H.; Hayashi, M. *Org. Lett.* **2003**, *5*, 3713–3715.
23. Barba, V.; Cuahutle, D.; Santillan, R.; Farfán, N. *Can. J. Chem.* **2001**, *79*, 1229–1237.
24. López-Ruiz, H.; Mera-Moreno, I.; Rojas-Lima, S.; Santillan, R.; Farfán, N. *Tetrahedron Lett.* **2008**, *49*, 1674–1677.
25. Abreu, A.; Alas, S. J.; Beltán, H. I.; Santillan, R.; Farfán, N. *J. Organomet. Chem.* **2006**, *691*, 337–348.
26. (a) Rodríguez, M.; Ochoa, M. E.; Rodríguez, C.; Santillan, R.; Barba, V.; Farfán, N. *J. Organomet. Chem.* **2007**, *692*, 2425–2435; (b) Rodríguez, M.; Ochoa, M. E.; Santillan, R.; Farfán, N.; Barba, V. *J. Organomet. Chem.* **2005**, *690*, 2975–2988.
27. *General procedure*: In a 100 mL round-bottomed flask containing a magnetic stirring bar was placed 1 equiv of (**1a–f**) in 45 mL of methanol, and 3 equiv of potassium cyanide was added. The resulting solution was stirred at room temperature for 4 h and the solvent was removed in vacuo. The crude product was purified by crystallization from methanol at 0 °C. The yields are those of pure compounds. Compound **3a**: mp 113–114 °C as a brown solid [lit.²⁹ 102 °C] (yield: 0.22 g, 61%) IR (KBr): ν_{\max} 3753, 2958, 1627, 1591, 1547, 751, 714 cm^{-1} ; ¹H NMR (400 MHz, CDCl₃): δ 11.58 (s, 1H, OH), 7.99 (dd, 1H, *J* = 7.6 Hz, *J* = 1.4 Hz, H-3), 7.42 (t, 1H, *J* = 6.5 Hz, H-5), 7.40 (d, 1H, *J* = 7.7 Hz, H-5'), 7.24 (t, 1H, *J* = 7.7 Hz, H-6'), 7.15 (d, 1H, *J* = 7.3 Hz, H-7'), 7.12 (d, 1H, *J* = 8.4 Hz, H-6), 6.99 (t, 1H, *J* = 7.5 Hz, H-4), 2.61 (s, 3H, CH₃) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 162.2 (C-2'), 158.6 (C-1), 148.8 (C-7a), 139.3 (C-3a), 133.4 (C-5), 129.8 (C-4'), 127.0 (C-3), 125.5 (C-7'), 125.1 (C-6'), 119.5 (C-4), 117.3 (C-6), 110.7 (C-2), 107.9 (C-3), 16.5 (CH₃) ppm. Anal. Calcd for C₁₄H₁₁NO₂: C, 74.65; H, 4.92; N, 6.22. Found: C, 74.57; H, 4.91; N, 6.48%. For **3b**: mp 146–147 °C as a purple solid [lit.²⁹ 140 °C] (yield: 0.25 g, 69%) IR (KBr): ν_{\max} 3649, 3153, 1628, 1588, 1541, 1254, 855, 805, 755, 708 cm^{-1} ; ¹H NMR (400 MHz, CDCl₃): δ 11.19 (s, 1H, OH), 7.95 (dd, 1H, *J* = 7.8 Hz, *J* = 1.6 Hz, H-3), 7.66 (d, 1H, *J* = 1.8 Hz, H-4'), 7.48 (d, 1H, *J* = 8.8 Hz, H-7'), 7.43 (ddd, 1H, *J* = 8.4 Hz, *J* = 6.9 Hz, *J* = 1.4 Hz, H-5), 7.31 (dd, 1H, *J* = 8.5 Hz, *J* = 2.0 Hz, H-6'), 7.09 (dd, 1H, *J* = 8.4 Hz, *J* = 0.7 Hz, H-6), 6.98 (td, 1H, *J* = 7.5 Hz, *J* = 1.0 Hz, H-4) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.2 (C-2'), 158.9 (C-1), 147.7 (C-7a), 141.1 (C-3a), 134.0 (C-5), 130.5 (C-5'), 127.2 (C-3), 125.6 (C-6'), 119.7 (C-4), 119.2 (C-4'), 117.6 (C-6), 111.3 (C-7'), 110.1 (C-2) ppm. Anal. Calcd for C₁₃H₈ClNO₂: C, 63.56; H, 3.28; N, 5.70. Found: C, 62.75; H, 3.11; N, 5.41%. For **3c**: mp 263–265 °C as a yellow solid (yield: 0.25 g, 67%) IR (KBr): ν_{\max} 3740, 2962, 2869, 1627, 1557, 1378, 830, 704 cm^{-1} ; Anal. Calcd for C₁₇H₁₇NO₂: C, 76.38; H, 6.41; N, 5.24. Found: C, 77.00; H, 6.04; N, 5.33%. Due to insolubility in CDCl₃, DMSO-*d*₆, acetone-*d*₆ etc., it was impossible to obtain NMR data. For **3d**: mp 136–137 °C as an orange solid [lit.³⁰ 128 °C] (yield: 0.25 g, 71%) IR (KBr): ν_{\max} 3648, 2966, 1631, 1590, 1543, 1256, 800, 755, 704 cm^{-1} ; ¹H NMR (400 MHz, CDCl₃): δ 11.52 (s, 1H, OH), 7.98 (dd, 1H, *J* = 7.8 Hz, *J* = 1.6 Hz, H-3), 7.48 (d, 1H, *J* = 0.7 Hz, H-4'), 7.44 (d, 1H, *J* = 8.4 Hz, H-6'), 7.42 (dd, 1H, *J* = 7.3 Hz, *J* = 1.4 Hz, H-5), 7.15 (d, 1H, *J* = 7.6 Hz, H-7'), 7.11 (d, 1H, *J* = 8.4 Hz, H-6), 6.99 (td, 1H, *J* = 8.0 Hz, *J* = 1.8 Hz, H-4), 2.47 (s, 3H, CH₃) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 163.0 (C-2'), 158.7 (C-1), 147.4 (C-7a), 140.2 (C-3a), 134.9 (C-5'), 133.4 (C-5), 127.0 (C-3), 126.5 (C-7'), 119.5 (C-4), 119.2 (C-6'), 117.4 (C-6), 110.7 (C-2), 110.0 (C-4'), 21.5 (CH₃) ppm. Anal. Calcd for C₁₄H₁₁NO₂: C, 74.65; H, 4.92; N, 6.22. Found: C, 74.88; H, 4.79; N, 6.35%. For **3e**: mp 125–126 °C as a pink solid [lit.³⁰ 122–124 °C] (yield: 0.21 g, 61%) IR (KBr): ν_{\max} 3527, 3029, 1630, 1587, 1487, 1259, 741, 705 cm^{-1} ; ¹H NMR (400 MHz, CDCl₃): δ 11.48 (s, 1H, OH), 8.01 (dd, 1H, *J* = 7.8 Hz, *J* = 1.6 Hz, H-3), 7.72–7.70 (m, 1H, H-5'), 7.60–7.57 (m, 1H, H-6'), 7.43 (td, 1H, *J* = 8.0 Hz, *J* = 1.4 Hz, H-5), 7.38–7.35 (m, 2H, H-10, H-4'), 7.12 (d, 1H, *J* = 8.4 Hz, H-6), 7.0 (td, 1H, *J* = 7.6 Hz, *J* = 0.9 Hz, H-4) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 162.9 (C-2'), 158.8 (C-1), 149.1 (C-7a), 140.0 (C-3a), 133.6 (C-5), 127.1 (C-3), 125.4 (C-7'), 125.0 (C-4'), 119.6 (C-4), 119.3 (C-5'), 117.4 (C-6), 110.7 (C-6'), 110.6 (C-2) ppm. Anal. Calcd for C₁₃H₉NO₂: C, 73.92; H, 4.29; N, 6.63. Found: C, 73.76; H, 4.21; N, 6.39%. For **3f**: mp 186–189 °C as a yellow solid (yield: 0.34 g, 94%) IR (KBr): ν_{\max} 3736, 3112, 1589, 1542, 757, 706, 546 cm^{-1} ; ¹H NMR (400 MHz, CDCl₃): δ 10.87 (s, 1H, OH), 8.70 (d, 1H, *J* = 2.4 Hz, H-7'), 8.32 (dd, 1H, *J* = 2.4 Hz, *J* = 8.7 Hz, H-5'), 8.04–8.00 (m, 2H, H-4' y H-3), 7.57 (t, 1H, *J* = 6.8 Hz, H-5), 7.14 (d, 1H, *J* = 8.2 Hz, H-6), 7.10 (t, 1H, *J* = 8.3 Hz, H-4) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 167.0 (C-2'), 158.7 (C-1), 149.0 (C-7a), 145.9 (C-3a), 145.4 (C-6'), 135.5 (C-5), 129.2 (C-4'), 121.6 (C-5'), 120.6 (C-4), 119.9 (C-3), 118.0 (C-6), 110.8 (C-2), 108.0 (C-7'). Anal. Calcd for C₁₃H₈N₂O₄: C, 60.94; H, 3.15; N, 10.93. Found: C, 60.84; H, 1.04; N, 10.81%.
28. Crystallographic data (excluding structure factors) for the structures in this Letter have been deposited with the Cambridge Crystallographic Data Centre as a Supplementary Publication Numbers, CCDC 713665 No. for **3a** Copy of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0) 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk].
29. Brewster, K.; Chittenden, R. A.; Harrison, J. M.; Inch, T. D. *J. Chem. Soc., Perkin Trans. I* **1976**, 1291–1296.
30. Stokker, G. *J. Org. Chem.* **1983**, *48*, 2613–2615.